title: Fotemustine in patients with relapsing malignant gliomas - a phase-ii trial.
abstract: Eleven patients with relapsing malignant glioma were treated with fotemustine chemotherapy, a new nitrosourea derivative. One partial response of 13 months duration occurred, resulting in a marked improvement of the quality of life of the patient. Seven patients had stable disease for a median duration of 5 months. Median survival from inclusion in the study was 6 months. Toxicity was mainly hematologic and manageable. We confirm that fotemustine has some activity in patients with relapsing malignant glioma.
authors: INST RECH INT SERV,BRUSSELS,BELGIUM. CTR HOSP TIVOLI,LA LOUVIERE,BELGIUM.
authors: C
authors: C
authors: Punt
authors: L
authors: L
authors: Stamatakis
authors: B
authors: B
authors: Gerard